Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Curently, Dr. Feld is clinician-scientist based at the Toronto Western Hospital Liver Clinic and the McLaughlin-Rotman Centre for Global Health.
Dr. Felds research focuses on understanding treatment non-response in hepatitis C and more broadly on understanding the antiviral immune response and developing new strategies for the treatment of viral hepatitis.
IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling.
Cytokine. 2018 Jun 13;:
N Engl J Med. 2018 Jun 14;378(24):2348-9
The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.
CMAJ. 2018 Jun 04;190(22):E677-E687
J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25058
Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B.
Diabetes Care. 2018 Mar 29;:
Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study.
J Rheumatol. 2018 Mar;45(3):378-384
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
J Viral Hepat. 2017 Dec 23;:
Aliment Pharmacol Ther. 2017 08;46(3):379-380
The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.
Aliment Pharmacol Ther. 2017 07;46(1):46-55
Scientist, Toronto General Hospital Research Institute (TGHRI)
Scientist, Sandra Rotman Centre for Global Health, Toronto, Ontario, Canada
Research Director, Gastroenterology, Medicine/University of Toronto, Francis Family Liver Clinic - Toronto Western Hospital, Toronto, Ontario, Canada
Associate Professor of Medicine, University of Toronto, Toronto, Ontario, Canada